StudyNo,Extracted by,Author,date_published,DOI,Title,date_first_admit,date_last_admit,date_fup,Country,Province,City,Study Population,All patients discharged/ dead?,Study design,End point,los_group,Diseases status,Disease status definition,Treatment,Treatment definition,ICU definition (if applicable / available),age_group,plot_cat,covid_severity,grouped_by_severity,other_feature_comorbidity,trt_group,other_group,outcome,N,perc_male,perc_male_specific_for_group,Age range,age_med,age_q25,age_q75,age_mean,age_sd,age_min,age_max,age_specific_for_group,LOS (unspecified),LOS (non-ICU),LOS ICU,LOS high flow nasal cannula,Symptom onset to admission,Symptom onset to discharge or death,Symptom onset to ICU admission,Symptom onset to death,Length of invasive mechanical ventilation,Length of non invasive mechanical ventilation,Length of oxygden support,Treatment to discharge,Treatment to death,LOS_med,LOS_q25,LOS_q75,LOS_mean,LOS_sd,LOS_min,LOS_max,LOS_nonICU_med,LOS_nonICU_q25,LOS_nonICU_q75,LOS_ICU_med,LOS_ICU_q25,LOS_ICU_q75,LOS_ICU_mean,LOS_ICU_sd,Issues/ biases with data,Notes,Included 
1,Emily,Bhatraju et al.,2020-03-30,DOI: 10.1056/NEJMoa2004500,Covid-19 in Critically Ill Patients in the Seattle Region - Case Series,2020-02-24,2020-03-09,2020-03-23,US,Washington,Seattle,"patients with laboratory-confirmed Covid-19 infection who were admitted to nine hospital ICUs in the Seattle region between February 24 and March 9, 2020",No,Case series,Discharge or death,general,,,,,,adult,main,All,N,,,,All,24,63,Y,64±18 [23–97] mean ± SD [range],,,,64,18,23,97,Y,12 (8-18),,9 (4-14) median (IQR),,7±4,,,,10 (7-12),,,,,12,8,18,,,,,,,,9,4,14,,,"12 (50%) had died, 4 (17%) had been discharged from the ICU but remained in the hospital, 3 (13%) were receiving mechanical ventilation and were still in the ICU, and 5 (21%) had been discharged from the hospital (so 7 patients censored)",,1
,,Bhatraju et al.,,,,,,,US,,,,No,,Survivors,general,,,,,,adult,main,All,N,,,,Alive,12,63,N,,,,,64,18,23,97,N,17 (16-23),,14 (4-17),,,,,,,,,,,17,16,23,,,,,,,,14,4,17,,,,,0
2,Yalda,Cai et al.,2020-04-02,https://doi.org/10.1111/all.14309,"COVID-19 in a Designated Infectious Diseases Hospital Outside Hubei Province, China.",2020-01-11,2020-02-06,2020-03-06,China,Shenzhen,,patients with confirmed COVID-19 admitted Third People's Hospital of Shenzhen,No,retrospective,Discharge or death,general,Allpatients,,,,,adult,main,All,Y,,,,All,298,48.66,Y,47.5 (33-61) median (IQR),47.5,33,61,,,,,Y,20.5 (15-26) median (IQR),,,,5 (2-7) median (IQR),,,,,,,,,20.5,15,26,,,,,,,,,,,,,,"Not all patients dead/discharge. ~10% missing. Not sure if LOS is based on total population, or on population dead and discharges",1
,,Cai et al.,,,,,,,China,,,,No,,Discharge or death,general,Non-severe,based on image assessment,,,,adult,,Non-severe,Y,,,,All,240,44.17,Y,41 (31-56) median IQR,41,31,56,,,,,Y,19 (15-25) median (IQR),,,,4.5 (2.0-7.0) median (IQR),,,,,,,,,19,15,25,,,,,,,,,,,,,,,0
,,Cai et al.,,,,,,,China,,,,No,,Discharge or death,general,Severe,based on image assessment,,,,adult,,Severe,Y,,,,All,58,67.24,Y,62.5 (56 - 66) median (IQR),62.5,56,66,,,,,Y,27 (21-34) median (IQR),,,,5 (4.0 - 6.8) median (IQR),,,,,,,,,27,21,34,,,,,,,,,,,,,,,0
3,Yalda,Cao et al.,2020-03-18,10.1056/NEJMoa2001282,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,2020-01-18,2020-02-03,2020-02-03,China,Hubei,Wuhan,"Laboratory-confirmed COVID-19 patients were enrolled Jin Yin-Tan Hospital, Wuhan, Hubei Province, China",No,RCT,Discharged or death,general/ICU,,,All,,,adult,main,All,N,,,,All,199,60.3,Y,58.0 (49.0–68.0) median (IQR),58,49,68,,,,,Y,15 (12 to 17) median (IQR),,10 (5 to 14),,,,,,5 (3 to 9) median (IQR),,13 (8 to 16) median (IQR),13 (10 to 16) median (IQR),10 (6 to 15) median (IQR),15,12,17,,,,,,,,10,5,14,,,Righ censored - only followed up for 28 days. Not completely clear on the number of deaths.,,1
,,Cao et al.,,,,,,,China,,,,No,,Discharge,general/ICU,,,All,,,adult,main,All,N,,,,Alive,155,60.3,N,,58,49,68,,,,,N,,,10 (8 to 17) median (IQR),,,,,,,,,,,,,,,,,,,,,10,8,17,,,,,0
,,Cao et al.,,,,,,,China,,,,No,,Death,general/ICU,,,All,,,adult,main,All,N,,,,Dead,44,60.3,N,,58,49,68,,,,,N,,,10 (4 to 14) median (IQR),,,,,,,,,,,,,,,,,,,,,10,4,14,,,,,0
,,Cao et al.,,,,,,,China,,,,No,,Discharged or death,general/ICU,,,lopinavir-ritonavir,"lopinavir-ritonavir: 400 mg and 100 mg, orally, twice daily plu standard of care:",,adult,,All,N,,lopinavir-ritonavir,lopinavir-ritonavir,All,99,61.6,Y,58.0 (50.0–68.0) median (IQR),58,50,68,,,,,Y,14 (12 to 17) median (IQR),,6 (2 to 11) median (IQR),,,,,,4 (3 to 7) median (IQR),,12 (9 to 16) median (IQR),12 (10 to 16) median (IQR),9 (6 to 13) median (IQR,14,12,17,,,,,,,,6,2,11,,,3 randomized to treatment died within 24 hours and did not receive treatment,,0
,,Cao et al.,,,,,,,China,,,,No,,Discharge,general/ICU,,,lopinavir-ritonavir,,,adult,,All,N,,lopinavir-ritonavir,lopinavir-ritonavir,Alive,80,61.6,N,,58,50,68,,,,,N,,,9 (5 to 44) median (IQR),,,,,,,,,,,,,,,,,,,,,9,5,44,,,,,0
,,Cao et al.,,,,,,,China,,,,No,,Death,general/ICU,,,lopinavir-ritonavir,,,adult,,All,N,,lopinavir-ritonavir,lopinavir-ritonavir,Dead,19,61.6,N,,58,50,68,,,,,N,,,6 (2 to 11) median (IQR),,,,,,,,,,,,,,,,,,,,,6,2,11,,,,,0
,,Cao et al.,,,,,,,China,,,,No,,Discharged or death,general/ICU,,,Standard treatment,,,adult,,All,N,,Standard treatment,Standard treatment,All,100,59,Y,58.0 (48.0–68.0) median (IQR),58,48,68,,,,,Y,16 (13 to 18) median (IQR),,11 (7 to 17) median (IQR),,,,,,5 (3 to 9) median (IQR),,13 (6 to 16) median (IQR),14 (11 to 16) median (IQR),12 (6 to 15) median (IQR),16,13,18,,,,,,,,11,7,17,,,,,0
,,Cao et al.,,,,,,,China,,,,No,,Discharge,general/ICU,,,Standard treatment,,,adult,,All,N,,Standard treatment,Standard treatment,Alive,75,59,N,,58,48,68,,,,,N,,,11 (9 to 14) median (IQR),,,,,,,,,,,,,,,,,,,,,11,9,14,,,,,0
,,Cao et al.,,,,,,,China,,,,No,,Death,general/ICU,,,Standard treatment,,,adult,,All,N,,Standard treatment,Standard treatment,Dead,25,59,N,,58,48,68,,,,,N,,,12 (7 to 17) median (IQR),,,,,,,,,,,,,,,,,,,,,12,7,17,,,,,0
4,Yalda,Cao et al.,2020-04-02,https://doi.org/10.1093/cid/ciaa243,"Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China.",2020-01-03,2020-02-01,2020-02-15,China,Hubei,Wuhan,All lab-confirmed patients with COVID-19 admitted to Wuhan University Zhongnan Hospital,Yes,cohort,Survival or death,general,All,,,,,adult,main,All,N,,,,All,102,52,Y,54(37-67) median (IQR),54,37,67,,,,,Y,11(7-15) median (IQR),,,,6(3-7) median (IQR),,,,,,,,,11,7,15,,,,,,,,,,,,,,,1
,,Cao et al.,,,,,,,China,,,,Yes,,,general,Survivors,,,,,adult,main,All,N,,,,Alive,17,76.5,Y,72(63-81) median (IQR),72,63,81,,,,,Y,9(6-17) median (IQR),,,,6(3-8) median (IQR),,,,,,,,,9,6,17,,,,,,,,,,,,,,,0
,,Cao et al.,,,,,,,China,,,,Yes,,,general,Non-survivors,,,,,adult,main,All,N,,,,Dead,85,47.1,Y,53(47-66) median (IQR),53,47,66,,,,,Y,11(7-14) median (IQR),,,,6(3-7) median (IQR),,,,,,,,,11,7,14,,,,,,,,,,,,,,,0
5,Yalda,Chen et al,2020-03-11,https://doi.org/10.1016/j.jinf.2020.03.004,"Clinical progression of patients with COVID-19 in Shanghai, China.",2020-01-20,2020-02-06,2020-02-25,China,Shanghai,,"recruited patients from Jan 20 to Feb 6, 2020, at Shanghai Public Health Clinical Center (SPHCC), Shanghai, China - diagnosed with COVID-19 according to Chinese national guideline for COVID-19 diagnosis and 
treatment, as well as the World Health Organization interim guidance",No,Retrospective cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,215,50.6,Y,51.0 (36.0–64.0) median (IQR),51,36,64,,,,,Y,16(12–20) median (IQR)?,,,,"4(2–7) median (IQR)*
*in patients with symptoms",,8.5 ± 4.0 mean sd?,,,,,,,16,12,20,,,,,,,,,,,,,right censored (only 86% patients completed follow up). Age and sex refers to the overall study population - not the population for LOS,,1
6,Ellie,Chen et al.,2020-03-26,https://doi.org/10.1136/bmj.m1091,Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study,2020-01-13,2020-02-12,2020-02-28,China,Hubei,Wuhan,"All covid-19 confirmed patients admitted to Tongji Hospital in Wuhan, China",No,Retrospective cohort,Discharge or death,general,"moderately, severely or critically ill",according to the guidance for corona virus disease 2019 (6th edition) released by the National Health Commission of China.,,,NA,adult,main,All,N,,,,All,274,62.4,Y,62.0 (44.0-70.0) median (IQR),62,44,70,,,,,Y,13.0 (6.0 - 17.0) median (IQR),,,,10.0 (7.0-12.0) median (IQR),22.0 (16.8 - 27.3) meadian (IQR),,,,,,,,13,6,17,,,,,,,,,,,,,,,1
,,Chen et al.,,,,,,,China,,,,No,,Discharge,general,,,,,NA,adult,main,All,N,,,,Alive,161,54.7,Y,51 (37 - 66) median (IQR),51,37,66,,,,,Y,16.0  (14.0 - 19.0) median (IQR),,,,9.0 (6.0-12.0) median (IQR),26.0 (21.8 - 29.0) median (IQR),,,,,,,,16,14,19,,,,,,,,,,,,,,,0
,,Chen et al.,,,,,,,China,,,,No,,Death,general,,,,,NA,adult,main,All,N,,,,Dead,113,73.4,Y,68 (62 - 77) median (IQR),68,62,77,,,,,Y,5.0 (3.0 - 9.3) median (IQR),,,,10.0 (7.0-13.0) median (IQR),16.0 (12.0 - 20.0) median (IQR),,16.0 (12.0 - 20.0) median (IQR),,,,,,5,3,9.3,,,,,,,,,,,,,,,0
7,Emily,Chen et al.,2020-03-06,https://doi.org/10.1101/2020.03.03.20030353,"Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study",2020-01-23,2020-02-14,2020-02-20,China,Hunan,,"From January 23 to February 14, 2020, all consecutive patients with confirmed COVID-19, admitted to the first Hospital of Changsha and Loudi Central Hospital in Hunan, China were recruited.",No,,Discharge,general,Discharged,,,,,adult,main,All,N,,,,Alive,159,49.8,N,47 (34-59) [1-84] median (IQR) [range],46,34,59,,,1,84,N,12 (10-15) median (IQR) range 5 - 25,,,,,,,,,,,,,12,10,15,,,5,25,,,,,,,,,,,1
,,Chen et al.,,,,,,,China,,,,No,,,general,Mild,,,,,adult,,Mild,N,,,,Alive,9,55.2,N,50 (34.5-53) [2-76],50,34.5,53,,,2,76,N,16 (12.5-21.5) (n = 9),,,,6 (3-11),,,,,,,,,16,12.5,21.5,,,,,,,,,,,,,,,0
,,Chen et al.,,,,,,,China,,,,No,,,general,Moderate,,,,,adult,,Moderate,N,,,,Alive,121,48.1,N,41 (32-53) [2-84],41,32,53,,,2,84,N,12 (9-14) (n = 121),,,,5 (3-8),,,,,,,,,12,9,14,,,,,,,,,,,,,,,0
,,Chen et al.,,,,,,,China,,,,No,,,general,Severe/critical,,,,,adult,,Severe,N,,,,Alive,29,54,N,60.5 (46-70) [1-82],60.5,46,70,,,1,82,N,14 (13-17) (n = 29),,,,6 (4-9),,,,,,,,,14,13,17,,,,,,,,,,,,,,,0
8,Ellie,Cheng et al ,2020-03-20,https://doi.org/10.1101/2020.02.18.20023242,Kidney disease is associated with in-hospital death of patients with COVID-19,2020-01-28,2020-02-11,2020-02-17,China,Hubei,Wuhan,"All COVID-19 patients admitted toTongji hospital, Tongji medical college, Huazhong university of science and technology",No,Consecutive cohort,Death,general,,,,,NA,adult,main,All,N,,,,Dead,113,52.4,N,63 (50–71),63,50,71,,,,,N,"6 days (interquartile range, 3–12 days)",,,,,,,,,,,,,6,3,12,,,,,,,,,,,,,LOS only reported for deaths,,1
9,Yalda,Ding et al.,2020-03-26,https://doi.org/10.1002/jmv.25781,"The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China.",,,,China,Hubei,Wuhan,"patients infected with both influenza and COVID-19 enrolled from Tongji Hospital, Tongji MedicalCollege, Huazhong University of Science and Technology",Yes,Case series,Discharge,general,,,,,,adult,main,All,N,,,,Alive,5,40,Y,39-66,49,,,50.2,,39,66,Y,"18.4 ± 7.02 (mean, sd)",,,,,,,,,,,,,,,,18.4,7.02,,,,,,,,,,,,,1
10,Yalda,Du et al.,2020-04-03,10.1164/rccm.202003-0543OC,Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study.,2020-01-09,2020-02-15,2020-02-15,China,Hubei,Wuhan,consecutive severe patients with confirmed COVID-19 admitted Hannan Hospital and Wuhan Union Hospital,Yes,retrospective observational,Death,general,Severe,unclear but seems to mean fatal.,,,,adult,main,Severe,N,,,,Dead,85,72.9,Y,65.8±14.2,,,,65.8,14.2,,,Y,"6.35 ± 4.51 
 (range 1 to 21) mean (sd)",,,,10.1 ± 6.2 mean (sd),,,,,,,,,,,,6.35,4.51,1,21,,,,,,,,,Only looked at deaths,first symptoms onset to ARDS: 10.3 ± 6.6 mean (sd),1
11,Ellie,Fan et al.,2020-03-05,https://doi.org/10.1101/2020.02.26.20026971 ,Clinical Features of COVID-19-Related Liver Damage,2020-01-20,2020-01-31,2020-02-19,China,,Shanghai," all  confirmed COVID-19 cases in Shanghai Public Health Clinical Center from January20 to January31, 2020",No,Retrospective cohort,Discharge,general,Normal and abnormal liver function,,,,NA,adult,main,All,N,,,,Alive,93,49.3,N,"50.5 years (interquartilerange,36-64)",50.5,36,64,,,15,88,N,12 days (6-21 days),,,,,,,,,,,,,,,,12,,6,21,,,,,,,,,,,1
,,Fan et al.,,,,,,,China,,,Normal liver function,No,,Discharge,general,,,,,,adult,,All,N,Normal liver function,,Normal liver function,Alive,27,38.4,N,,50.5,36,64,,,,,N,12.67±5.31,,,,,,,,,,,,,,,,12.67,5.31,,,,,,,,,,,,,0
,,Fan et al.,,,,,,,China,,,"Abnormal liver function (abnormal liver damage was defined as any parameter more than the upper 
limit of normal value (ULN) of ALT (40 U/L), AST（35 U/L), ALP(100 U/L), 
GGT(45 U/L), TB(20.5 umol/L), LDH(245 U/L))",No,,Discharge,general,,,,,,adult,,All,N,Abnormal liver function,,Abnormal liver function,Alive,66,62.7,N,,50.5,36,64,,,,,N,15.14±4.58,,,,,,,,,,,,,,,,15.14,4.58,,,,,,,,,,,,,0
12,,Graselli et al,2020-04-06,doi:10.1001/jama.2020.5394,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",2020-02-20,2020-03-18,2020-03-25,Italy,Lombardy,,"All consecutive patients with laboratory-confirmed SARS-CoV-2 infection, referred to Ospedale Maggiore Policlinico, and subsequently admitted to one of the ICUs among 72 hospitals in the network between February 20 and March 18, 2020, were enrolled.",No,Case series,ICU discharge/death,ICU,,,,,,adult,main,Severe,N,,,,All,1591,82,Y,63 (56-70) median (IQR),63,56,70,,,,,Y,,,9 (6-13) median (IQR),,,,,,,,,,,,,,,,,,,,,9,6,13,,,,,1
,,Graselli et al,,,,,,,Italy,,,Patients discharged from ICU,No,,ICU discharge,ICU,,,,,,adult,main,Severe,N,,,,Alive,256,82,N,,63,56,70,,,,,N,,,8 (5-12) ,,,,,,,,,,,,,,,,,,,,,8,5,12,,,,,0
,,Graselli et al,,,,,,,Italy,,,Patients who died in ICU,No,,Death,ICU,,,,,,adult,main,Severe,N,,,,Dead,405,82,N,,63,56,70,,,,,N,,,7 (5-11),,,,,,,,,,,,,,,,,,,,,7,5,11,,,,,0
13,Yalda,Guan et al.,2020-02-28,DOI: 10.1056/NEJMoa2002032,Clinical Characteristics of Coronavirus Disease 2019 in China.,2020-12-11,2020-01-29,2020-01-31,China,,,Hospitalized lab confirmed cases from 552 hospitals in 30 provinces,No,Cohort,Discharge and death,general,,,,,,adult,main,All,Y,,,,All,1099,58.1,Y,47.0 (35.0 - 58.0) median (IQR),47,35,58,,,,,Y,12.0(10.0 - 14.0) median IQR,,,,,,,,,,,,,12,10,14,,,,,,,,,,,,,right censored. Not all patients in this study were hospitalised (1029 /1099),,1
,,Guan et al.,,,,,,,China,,,,No,,Discharge and death,general,Non-severe,American Thoracic Society guidelines for community-acquired pneumonia,,,,adult,,Non-severe,Y,,,,All,926,58.2,Y,45 (34.0 - 57.0) median (IQR),45,34,57,,,,,Y,11.0 (10.0 - 13.0) median IQR,,,,,,,,,,,,,11,10,13,,,,,,,,,,,,,,,0
,,Guan et al.,,,,,,,China,,,,No,,Discharge and death,general,Severe,,,,,adult,,Severe,Y,,,,All,173,57.8,Y,52.0 (40.0 - 65.0),52,40,65,,,,,Y,13.0 (11.5 - 17.0) median IQR,,,,,,,,,,,,,13,11.5,17,,,,,,,,,,,,,,,0
14,Emily,ICNARC,2020-04-16,https://www.icnarc.org/DataServices/Attachments/Download/c31dd38d-d77b-ea11-9124-00505601089b,ICNARC report on COVID-19in critical care,,2020-04-16,,UK,,,patients critically ill with confirmed COVID-19 reported to ICNARC up to 4pm on 16 April 2020 from critical care units participating in the Case Mix Programme,No,,Discharge,ICU,Severe (HDU/ICU),,,,,adult,main,Severe,N,,,,Alive,1437,46.7,Y,"60 (52, 68) median (IQR) / 59.5 (12.6) mean (SD)",60,52,68,59.5,12.6,,,N,,,"5 (2, 9) median (IQR)",,,,,,,,,,,,,,,,,,,,,5,2,9,,,,,1
,,ICNARC,,,,,,,UK,,,,No,,Death,ICU,Severe (HDU/ICU),,,,,adult,main,Severe,N,,,,Dead,1499,53.3,Y,"60 (52, 68) median (IQR) / 59.5 (12.6) mean (SD)",60,52,68,59.5,12.6,,,N,,,"6 (4, 10) median (IQR)",,,,,,,,,,,,,,,,,,,,,6,4,10,,,,,1
15,Ellie,ISARIC,2020-04-08,https://media.tghn.org/medialibrary/2020/04/ISARIC_Data_Platform_COVID-19_Report_8APR20.pdf,International Severe Acute Respiratory and Emerging InfectionsConsortium (ISARIC),,2020-03-25,,Worldwide (25 countries),,,Patient details were submitted electronically by participating sites to the ISARIC database. Confirmed or suspected COVID-19 cases. ,No,Cohort,All (including still hospitalised),,,,,,,adult,,All,N,,,,All,3316,53,Y,71 (median) range (0-104),71,,,,,0,104,Y,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Age and sex is only available for all patients. Majority of data is from the UK (82%),0
,,ISARIC,,,,,,,Worldwide (25 countries),,,,No,,Discharge or death,general,,,,,,adult,main,All,N,,,,All,1567,53,N,,71,,,,,0,104,N,7.2 (SD 6.6),,,,,,,,,,,,,,,,7.2,6.6,,,,,,,,,,,,,1
,,ISARIC,,,,,,,Worldwide (25 countries),,,,No,,Discharge or death,ICU,,,,,,adult,main,All,N,,,,All,244,53,N,,71,,,,,0,104,N,,,6.3 days (SD: 5.2 days) ,,,,,,,,,,,,,,,,,,,,,,,,6.3,5.2,,,0
16,Emily,Liu et al.,2020-03-13,https://doi.org/10.1101/2020.03.09.20033118,"Epidemiological, Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis",2020-01-16,2020-02-15,,China,Hubei,Wuhan,"confirmed cases of novel coronavirus-infected medical staff admitted to Union Hospital, Wuhan between 16 Jan, 2020 to 15 Feb, 2020",No,,Discharge,general,,,,,,adult,main,All,N,,,,Alive,64,36,Y,35 (29-43) median (IQR),35,29,43,,,,,Y,12.5 (9-19.8) median (IQR),,,,8.5 (4.3-15) median (IQR),,,,,,,,,12.5,9,19.8,,,,,,,,,,,,,30/64 incomplete FUP,2 patients without date of onset not grouped,1
,,Liu et al.,,,,,,,China,,,onset-admission <= 10days,No,,,general,,,,,,adult,,All,N,onset-admission <= 10 days,,onset-admission <= 10 days,Alive,37,46,Y,37 (32-44),37,32,44,,,,,Y,18 (13-20.5),,,,5 (3-7),,,,,,,,,18,13,20.5,,,,,,,,,,,,,,,0
,,Liu et al.,,,,,,,China,,,onset-admission > 10days,No,,,general,,,,,,adult,,All,N,onset-admission > 10 days,,onset-admission > 10 days,Alive,25,24,Y,30 (27-36),30,27,36,,,,,Y,9 (6-11),,,,18 (14-24),,,,,,,,,9,6,11,,,,,,,,,,,,,,,0
17,Yalda,Liu et al.,2020-03-12,https://doi.org/10.1016/j.ijid.2020.03.013,Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression,2020-01-22,2020-02-11,2020-02-11,China,Hangzhou,,"patients whose disease confirmed by two consecutive positive results of SARS-CoV-2 RNA, admitted to Xixi hospital",No,Cohort,"Discharged (3 transferred, 7 discharged)",general,,,lopinavir,,,adult,main,All,N,,,,Alive,10,40,Y,42 ( 34–50) median (IQR),42,34,50,,,,,Y,13 (4–17) median (IQR),,,,,,,,,,,,,13,4,17,,,,,,,,,,,,,right censored(follow-up completed for 7/10 - 3 transferred to ICU),,1
18,Emily,Liu et al. ,2020-02-23,https://doi.org/10.1101/2020.02.20.20025536,"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China",2020-01-20,2020-02-03,,China,Chongqing,,"hospitalized patients with confirmed COVID-19 at Chongqing University Three Gorges Hospital in Chongqing, China, from January 20 to February 3, 2020",Yes,,Discharge or death,general,All,,,,,adult,main,All,Y,,,,All,51,62.7,Y,"45 years (interquartile range, 34-51; range, 16-68 years)",45,34,51,,,16,68,Y,12 (9-13) median (IQR),,,,,,,,,,,,,12,9,13,,,,,,,,,,,,,,"One death, all others discharged",1
,,Liu et al. ,,,,,,,China,,,,Yes,,,general,Non-Severe,,,,,adult,,Non-severe,Y,,,,All,44,63.7,Y,44 (33-49),44,33,49,,,,,Y,12 (9-13),,,,,,,,,,,,,12,9,13,,,,,,,,,,,,,,,0
,,Liu et al. ,,,,,,,China,,,,Yes,,,general,Severe,World Health Organization interim guidance/The National Health and Health Commission of the people's Republic of China,,,,adult,,Severe,Y,,,,All,7,57.1,Y,52 (44-60),52,44,60,,,,,Y,15 (9-16),,,,,,,,,,,,,15,9,16,,,,,,,,,,,,,,,0
19,Yalda,Mo et al.,2020-03-16,https://doi.org/10.1093/cid/ciaa270,"Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China.",2020-01-01,2020-02-05,,China,Hubei,Wuhan,All consecutive patients with confirmed COVID-19 admitted to Zhongnan Hospital of Wuhan University from January 1st to February 5th were enrolled,No,Retrospective cohort,Death,general,,,,,,adult,main,All,N,,,,Dead,22,,,,,,,,,,,,10.5 (8~16) median (IQR),,,,,,,,,,,,,10.5,8,16,,,,,,,,,,,,,"Low quality
follow-up date not clear",,1
,,Mo et al.,,,,,,,China,,,,No,,Recovered,general,,,,,,adult,main,All,N,,,,Alive,,,,,,,,,,,,,10 (7~15) median (IQR),,,,,,,,,,,,,10,7,15,,,,,,,,,,,,,,,1
20,Emily,Pan et al.,2020-02-13,https://doi.org/10.1148/radiol.2020200370,Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia.,2020-01-12,2020-02-06,,China,Hubei,Wuhan,"patients with RT-PCR confirmed COVID-19 infection presenting between 12 January 2020 to 6 February 2020 at Union Hospital, TongjiMedical College. Patients with severe respiratory distress and/ or oxygen requirement at any time during the disease course were excluded",Yes,Case series,Discharge,general,,,,,,adult,main,Non-severe,N,,,,Alive,21,29,Y,40 ± 9 [25 -63] mean±SD [range],,,,40,9,25,63,Y,17 ± 4 [11 -26] mean±SD [range],,,,,,,,,,,,,,,,17,4,11,26,,,,,,,,,Severe cases excluded,,1
21,Emily,Qi et al.,2020-03-03,https://doi.org/10.1101/2020.03.01.20029397,"Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study",2020-01-19,2020-02-16,2020-02-16,China,Chongqing,," laboratory-confirmed  COVID-19  patients admitted to 3 designated-hospitals (Qianjiang central hospital of Chongqing, Chongqing three gorges central hospital and Chongqing public health medical center) in  Chongqing  provincial  municipality  from  January  19  to  February  16,  2020",No,Retrospective cohort,Death or discharge (not clear),general,All,,,,,adult,main,All,Y,,,,All,164,55.8,Y,48 (35-65) [20-80] median (IQR) [range],48,35,65,,,20,80,Y,15 (11.5-16) [9-25] (median(IQR) [range]),,,,7 (3-10) median (IQR),,,,,,,,,15,11.5,16,,,9,25,,,,,,,,,"160/267 incomplete FUP. Not obvious when they report LOS, whether they have included patients still admitted to hospital (n =160) or limited to only those that have been dead of discharged",,1
,,Qi et al.,,,,,,,China,,,,No,,,general,Severe,American Thoracic Society guideline,,,,adult,,Severe,Y,,,,All,44,78,Y,71.5 (65.8-77) [39-80],71.5,65.8,77,,,39,80,Y,20 (17.5-23.25) [14-25],,,,9 (6-12.75),,,,,,,,,20,17.5,23.25,,,14,25,,,,,,,,,,,0
,,Qi et al.,,,,,,,China,,,,No,,,general,Non-severe,,,,,adult,,Non-severe,Y,,,,All,120,50.7,Y,43 (32.5-57) [20-79],43,32.5,57,,,20,79,Y,14 (11-16) [9-16],,,,6 (3-9),,,,,,,,,14,11,16,,,9,16,,,,,,,,,,,0
22,Ellie,Qui et al,2020-03-25,https://doi.org/10.1016/S1473-3099(20)30198-5,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study",2020-01-17,,2020-03-01,China,Zhejiang,Wenzhou," paediatric patients (aged 0–16 years) with confirmed COVID-19 from electronic medical records in three hospitals in Zhejiang, China (Ningbo Women and Children's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, and Wenzhou Central Hospital of Wenzhou)",Yes,Retrospective cohort,Discharge,general,Mild and moderate cases,,,,NA,pediatric,main,Non-severe,Y,,,,Alive,36,63.9,Y,"Age 8·3 (3·5, 1–16) mean (SD, range)",,,,8.3,3.5,1,16,Y,"14 (3, 10-20) mean (SD, range)",,,,,,,,,,,,,,,,14,3,10,20,,,,,,,,,,No severe and critical patients identified,1
,,Qui et al,,,,,,,China,,,,Yes,,Discharge,general,Mild cases,"Upper respiratory symptoms (eg, pharyngeal congestion, sore throat, and fever) for a short duration or asymptomatic infection; Positive RT-PCR test for SARS-CoV-2; No abnormal radiographic and septic presentation",,,,pediatric,,Mild,Y,,,,Alive,17,59,Y,"Age 7.5 (3·2, 1–16) mean (SD, range)",,,,7.5,3.2,1,16,Y,"12 (3, 10–16) mean (SD, range)",,,,,,,,,,,,,,,,12,3,10,16,,,,,,,,,,,0
,,Qui et al,,,,,,,China,,,,Yes,,Discharge,general,Moderate cases,"Mild pneumonia; Symptoms such as fever, cough, fatigue, headache, and myalgia; No complications and manifestations related to severe conditions",,,,pediatric,,Moderate,Y,,,,Alive,19,68,Y,"Age 9.0 (3.6, 1–16) mean (SD, range)",,,,9,3.6,1,16,Y,"15 (4, 12–20) mean (SD, range)",,,,,,,,,,,,,,,,15,4,12,20,,,,,,,,,,,0
23,Emily,Shen et al.,2020-03-27,10.1001/jama.2020.4783,Treatment of 5 Critically Ill Patients WithCOVID-19 With Convalescent Plasma,2020-01-20,2020-03-25,2020-03-25,China,Shenzen,,"laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the
following criteria: severe pneumonia with rapid progression and continuously high viral load
despite antiviral treatment; PAO2/FIO2 <300; and mechanical ventilation (Shenzhen Third People's Hospital)",No,Cohort,Discharge (3) & still hospitalised (2),general,Severe (ARDS),,,,,adult,,Severe,N,,,,Alive,5,60,Y,[36-73],55,,,,,36,73,Y,,,,,2 [2-4] median [range],,,,,,,,,,,,,,,,,,,,,,,,"Very small sample size. Sample size for LOS is 3, but sample size for onset to admission is 5",,0
,,Shen et al.,,,,,,,China,,,,No,,Discharge,general,,,,,,adult,main,Severe,N,,,,Alive,3,60,N,,55,,,,,36,73,N,"51, 53, 55 days",,,,,,,,,,,,,53,,,,,51,55,,,,,,,,,,,1
24,Ellie,Shi et al.,2020-03-10,http://dx.doi.org/10.21037/atm.2020.03.22,"A quickly, effectively screening process of novel corona virus disease 2019 (COVID-19) in children in Shanghai, China.",2020-01-19,2020-02-08,2020-02-15,China,Shanghai,,"Children admitted to outpatient and emergency department Children’s Hospital of Fudan University, Shanghai ",No,Prospective cohort,Study end (4 discharged - remaining 6 still hospitalised at study end),general,,,,,NA,pediatric,main,All,N,,,,Alive,10,50,Y,"7 months to 11 years, the average age is 6.0±4.2",,,,6,4.2,0.58,11,Y,10 days (average),,,,,,,,,,,,,,,,10,,,,,,,,,,,,Only 4 patients had been discharged when LOS was calculated. No IQR range,,1
25,Emily,Shi et al.,2020-04-08,https://doi.org/10.1101/2020.03.28.20046144,The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study,2020-02-02,2020-03-16,,China,Hubei,Wuhan,"patients with COVID-19 (severe  clinical  classification) treated at the hospital  (Union  Hospital,  Tongji  Medical  College,  Huazhong  University  of  Science and Technology) between February 1 and March 15, 2021",Yes,,Discharge,general,,,Heparin,low 50 molecular weight heparin (LMWH),,adult,main,Severe,N,,Heparin,Heparin,Alive,21,62,Y,69 [42-91] median [range],69,,,,,42,91,Y,29 (17-42) (IQR),,,,,,,,,,,,,29,17,42,,,,,,,,,,,,,No critical cases,,1
,,Shi et al.,,,,,,,China,,,,Yes,,,general,,,Control,,,adult,main,Severe,N,,Control,Control,Alive,21,67,Y,69 [40-84],69,,,,,40,84,Y,27 (24-31),,,,,,,,,,,,,27,24,31,,,,,,,,,,,,,,,1
26,Yalda,Shi et al.,2020-03-25,10.1001/jamacardio.2020.0950,"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.",2020-01-20,2020-02-10,2020-02-15,China,,Wuhan,"consecutive admitted patients with laboratory-confirmed COVID-19  at Renmin Hospital 

                                
                        
                
        ",No,retrospective cohort,Death,general,Cardiac injury,"blood levels of cardiac biomarkers (hs-TNI) above the 99th-percentile upper reference limit, regardless of new abnormalities in electrocardiography and echocardiograph",,,,adult,main,All,N,Cardiac injury,,Cardiac injury,Dead,42,53.7,Y,74 (34-95),74,,,,,34,95,Y,6.3 (1 - 16) mean (range),,,,,,,15.6 (1 - 37) mean(range),,,,,,,,,6.3,,1,16,,,,,,,,,Only report LOS for those who have died: 77% remained in hospital,Age and sex for whole population - not just the deaths.,1
,,Shi et al.,,,,,,,China,,,,No,,,general,No cardiac injury,,,,,adult,main,All,N,No cardiac injury,,No cardiac injury,Dead,15,48.2,Y,60 (21-90),60,,,,,21,90,Y,7.8 (1 - 23) mean (range),,,,,,,16.9 (3 -37) mean(range),,,,,,,,,7.8,,1,23,,,,,,,,,,,1
27,Yalda,Shi et al.,2020-02-24,https://doi.org/10.1016/S1473-3099(20)30086-4,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.",2020-12-20,2020-01-23,2020-02-08,China,,Wuhan,admitted to Wuhan Jinyintan hospital or Union Hospital of Tongji Medical College with COVID and underwent serial chest scans ,No,retrospective cohort,Discharge,general,type 1,"initial progression to peak level, followed by radiographic improvement",,,,adult,main,All,N,type 1,,type 1,Alive,24,,,,,,,,,,,,25 (20–27) median (IQR),,,,,,,,,,,,,25,20,27,,,,,,,,,,,,,,,1
,,Shi et al.,,,,,,,China,,,,No,,,general,type 3,radiographic improvement,,,,adult,main,All,N,type 3,,type 3,Alive,5,,,,,,,,,,,,19 (11-25) median (IQR),,,,,,,,,,,,,19,11,25,,,,,,,,,,,,,,,1
28,Yalda,Spiteri et al.,2020-03-05,https://doi.org/10.2807/1560-7917.ES.2020.25.9.2000178,"First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.",2020-01-24,2020-02-21,2020-02-21,EU/EEA,,,european surveillance data,No,Surveillance,Discharge,general,,,,,,adult,main,All,N,,,,Alive,16,,,,,,,,,,,,13 (8–23) median (range),,,,,,,,,,,,,13,,,,,8,23,,,,,,,,,,,1
,,Spiteri et al.,,,,,,,EU/EEA,,,,No,,Death,general/ICU,,,,,,adult,main,All,N,,,,Dead,1,,,,,,,,,,,,21,,19,,,,,,,,,,,21,,,,,,,,,,19,,,,,,,1
29,Emily,Tang et al.,2020-03-26,https://doi.org/10.1016/j.chest.2020.03.032,Comparison of Hospitalized Patients with Acute Respiratory Distress Syndrome Caused by COVID-19 and H1N1,2019-12-24,2020-02-07,,China,Hubei,Wuhan,"patients with COVID-19-induced ARDS admitted to the Department of Pulmonary and Critical Care at Wuhan Pulmonary Hospital in Hubei Province of China between December 24, 2019 and February 7, 2020. ",No,Retrospective case-control,Discharge or death,general,,,,,,adult,main,All,N,,,,All,73,61.6,Y,67 (57-72) median (IQR),67,57,72,,,,,Y,13 (10-18) median (IQR),,,,,,,,,,,,,13,10,18,,,,,,,,,,,,,"Unclear whether LOS censored for patients remaining in hospital, or if they were excluded",,1
30,Ellie,Tian et al.,2020-03-23,https://doi.org/10.1101/2020.03.21.20038778 ,"Clinical characteristics and reasons of different duration from onset to
 release from quarantine for patients with COVID-19 Outside Hubei 
province, China.",Not provided,Not provided,Not provided,China,,Liacheng city,Liaocheng city,Yes,Retrospective cohort,Unknown,general,"mild (13.5%), moderate (81.1%), severe (2.7%), and critical (2.7%)",,,,,adult,main,All,N,,,,All,37,45.9,Y,44.3±1.67,,,,44.3,1.67,,,Y,"16.1  ±6.2  [7,32]",,,,4.1±3.7,,,,,,,,,,,,16.1,6.2,7,32,,,,,,,,,"Really unclear what the study population is (don't mention the hospital explicitely- from the ethics I think it was Liaochen Peoples Hospital), and the period over which patients were admitted to hospital",,1
31,Emily,Wang et al.,2020-03-20,doi: 10.1016/j.jinf.2020.03.019,Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up,2020-01-01,2020-02-06,2020-03-05,China,Hubei,Wuhan," all confirmed cases of COVID-19 over 60 years old admitted from Jan 1 to Feb 6 at isolation ward of Renmin Hospital of Wuhan University in Wuhan, China.",No,Case series,"Discharge, hospitalised, or death",general,,,,,,elderly,main,All,N,,,,All,339,49,Y,69 (65-76) median (IQR),69,65,76,,,,,Y,28 (15-28) median (IQR),,,,10 (7-14) median (IQR),,,,,,,,,28,15,28,,,,,,,,,,,,,,,1
,,Wang et al.,,,,,,,China,,,survived (discharged or still in hospital),No,,Discharge or hospitalised,general,,,,,,elderly,main,All,N,,,,Alive,274,46.4,Y,68 (64-74),68,64,74,,,,,Y,28 (26-29),,,,10 (7-13),,,,,,,,,28,26,29,,,,,,,,,,,,,"Survival includes both discharged and patients still hospitalised. 91 cases were discharged (26.8%), 183 cases (54.0%) stayed in hospital and 65 cases (19.2%) were dead",,0
,,Wang et al.,,,,,,,China,,,dead,No,,Death,general,,,,,,elderly,main,All,N,,,,Dead,65,60,Y,76 (70-83),76,70,83,,,,,Y,5 (3-8),,,,10 (7-14),,,,,,,,,5,3,8,,,,,,,,,,,,,Majority of LOS right-truncated,Patients over 60yo.,0
32,Emily,Wei et al.,2020-02-26,DOI: 10.1002/ppul.24718,Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults.,2020-01-23,2020-02-08,2020-02-18,China,Hubei,Wuhan,Pediatric inpatients with COVID-19 infection confirmed by pharyngeal swab in Wuhan Children's hospital,No,Cohort,Discharge,general,,,,,,pediatric,main,All,N,,,,Alive,18,65,Y,2y [1 day - 14y] median [range],2,,,,,0.002739726027,14,Y,12.9 [8 -20] average [range],,,,,,,,,,,,,,,,12.9,,8,20,,,,,,,,,Statistic used for LOS not completely clear. 2 neonates remain under observation but had negative CT findings.,,1
33,Ellie,Wu et al.,2020-02-30,https://doi.org/10.1101/2020.02.26.20028590,Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19),2019-12-26,2020-01-28,2020-02-12,China,Hubei,Wuhan,"From Dec 25, 2019 to Jan 27, 2020, COVID-19 patients  admitted  to  Wuhan Jinyintan Hospital (Hubei, China) were selected.  ",Yes,Retrospective cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,145,63.3,N,,,,,51.9,14.26,,,N,12 (9-14),,,,,,,,,,,,,12,9,14,,,,,,,,,,,,,,Don't specify what LOS is - I think it's means ±SD,1
,,Wu et al.,,,,,,,China,,,,Yes,,Death,general,,,,,,adult,main,All,N,,,,Dead,43,63.3,N,,,,,51.9,14.26,,,N,7 (4-11),,,,,,,,,,,,,7,4,11,,,,,,,,,,,,,,,1
34,Yalda,Wu et al.,2020-02-29,https://doi.org/10.1093/cid/ciaa199,Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study.,2020-01-22,2020-02-14,2020-02-14,China,Jiangsu,,"All admitted patients for COVID-19 to First People’s Hospital of Yancheng City, the Second People’s Hospital of Yancheng City, and the Fifth People’s Hospital of Wuxi. cases: any of: epidemiological history, any 2 clinical manifestations and the pathogenic evidence",No,retrospective cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,21,48.75,Y,46.10 ± 15.42,,,,46.1,15.42,,,Y,mean: 8,,,,,,,,,,,,,,,,8,,,,,,,,,,,,80 patients but LOS only reported for those discharged. Numbers don't add up in table 1. Age and sex refer to overall population,,1
35,Emily,Wu et al.,2020-03-13,doi:10.1001/jamainternmed.2020.0994,"Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China.",2019-12-25,2020-01-26,2020-02-13,China,Hubei,Wuhan,"confirmed COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital in China betweenDecember 25, 2019, and January 26, 2020",No,Retrospective cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,144,63.7,Y,51 (43-60) median (IQR),51,43,60,,,,,Y,13 (10-16) median (IQR),,,,,,,,,,,,,13,10,16,,,,,,,,,,,,,Unclear whether LOS included those who died. State that some of their cases have previously been described in other studies. Age and sex are regarding total population (including those remaining in hospital),,1
36,Emily,Xie et al.,2020-04-02,https://doi.org/10.1111/liv.14449,Clinical characteristics of Non‐ICU hospitalized patients with coronavirus disease 2019 and liver injury：A Retrospective study,2020-02-02,2020-02-23,,China,Hubei,Wuhan,"non-ICU  Ward  at  Wuhan  Jinyintan  Hospital.  All  consecutive discharged  patients  treated  by  Fujian  Medical  Team  to  aid  Hubei  province  were  enrolled  in  the  study  between February 2, 2020 and February 23, 2020.",Yes,Retrospective cohort,,,all,,,,,adult,main,Non-severe,N,,,,Alive,79,55.7,Y,60 (48-66) median (IQR),60,48,66,,,,,Y,,,,,12 median,,,,,,,,,,,,,,,,,,,,,,,,,Non-ICU. Dates are based on discharge -not admission,1
,,Xie et al.,,,,,,,China,,,,Yes,,,ICU,with liver injury,,,,,adult,,Non-severe,N,with liver injury,,with liver injury,Alive,50,44.7,Y,56(45-65) ,56,45,65,,,,,Y,,11.4 (8.5-14),,,,,,,,,,,,,,,,,,,11.4,8.5,14,,,,,,,,0
,,Xie et al.,,,,,,,China,,,,Yes,,,ICU,without liver injury,,,,,adult,,Non-severe,N,without liver injury,,without liver injury,Alive,29,72.4,Y,62 (46-67),62,46,67,,,,,Y,,15.4 (11-16.8),,,,,,,,,,,,,,,,,,,15.4,11,16.8,,,,,,,,0
37,Emily,Xu et al.,2020-03-26,https://doi.org/10.1101/2020.03.24.20042408,Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis,2020-01-01,2020-02-20,,China,Hubei/Anhui,,"diagnosed as COVID-19 from January 1 to January 30, 2020, recruited from Union Hospital of Huazhong University of Science and Technology, in Wuhan city, Hubei Province. diagnosed as COVID-19 from January 25 to February 20, 2020, recruited from the Second People’s Hospital of Fuyang City, in Anhui province.",No,,Death or discharge,general,,,,,,adult,main,All,N,,,,All,355,54.4,Y,< 50 (45%); 50-69 (41.6%); >=70 (13.2%),59.5,,,,,,,N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LOS only mentioned amongst those with AKI who died. Sex/age distribution not specified for this subgroup,,1
,,Xu et al.,,,,,,,China,,,Acute kidney injury (AKI),No,,Death,general,,,,,,adult,,All,N,Acute kidney injury (AKI),,Acute kidney injury (AKI),Dead,56,54.4,N,,59.5,,,,,,,N,10.9 mean,,,,,,,,,,,,,,,,10.9,,,,,,,,,,,,,,0
38,Emily,Yan et al.,2020-03-30,https://doi.org/10.1101/2020.03.22.20040832,Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection,2020-01-31,2020-03-09,,China,Hubei,,"hospitalized, non-critically ill patients with SARS-CoV-2 infection during 31January to 09 March 2020, and had the available RNA viral  data  to estimate  the duration of  viral  shedding (NO.3 People’s Hospital of Hubei province)",No,,Discharge,general,,,,,,adult,main,All,N,,,,Alive,120,45,Y,52 (35-63) median(IQR),52,35,63,,,,,Y,21 (17-26) median (IQR),,,,,,,,,,,,,21,17,26,,,,,,,,,,,,,"Investigating viral shedding so only included patients with RNA viral data. Most patients (99.2%) in our cohort were non-critically ill patients with COVID-19 due to triage strategies. Had 168 pateints admitted over the study period, only reported LOS for 120 that had been discharged - so censoring of data",Longer LOS as retained in hospital to continue assessment for viral shedding?,1
,,Yan et al.,,,,,,,China,,,,No,,,general,,,Lopinavir/Ritonavir,"LPV/ r (400mg and 100mg , orally, twice daily",,adult,,All,N,,Lopinavir/Ritonavir,Lopinavir/Ritonavir,Alive,78,44.9,Y,50 (34-61),50,34,61,,,,,Y,23 (19-27),,,,,,,,,,,,,23,19,27,,,,,,,,,,,,,,,0
,,Yan et al.,,,,,,,China,,,,No,,,general,,,Control,,,adult,,All,N,,Control,Control,Alive,42,45.2,Y,57 (36.5-66),57,36.5,66,,,,,Y,18.5 (13-22.5),,,,,,,,,,,,,18.5,13,22.5,,,,,,,,,,,,,,,0
39,Ellie,Yan et al.,2020-03-20,https://doi.org/10.1097/CM9.0000000000000824,"Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study.",2020-01-01,,2020-02-21,China,"Wuhan, Hubei",,"Recovered and dead patients admitted two tertiary hospitals in Wuhan (Hankou and Caidian branch of Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, and Hankou branch of Central Hospital of Wuhan) from January 1, 2020 to February 21, 2020. ",Yes,Case cohort,Discharged,general,,,,,,adult,main,All,N,,,,Alive,116,44,Y,"40 (33, 57) median (Q1,Q3)",40,33,57,,,,,Y,"16 (12, 20) median (Q1,Q3)",,,,"7.0 (5.0, 10.0) median (IQR)",,,,,,,,,16,12,20,,,,,,,,,,,,,"Bit difficult to say whether follow-up was completed, as they only enrolled dead and discharged patients within the study, but there were actually more patients that were still hospitalised",,1
,,Yan et al.,,,,,,,China,,,,Yes,,Death,general,,,,,,adult,main,All,N,,,,Dead,109,67,Y,"69 (62, 74) median (Q1,Q3)",69,62,74,,,,,Y,"8 (4, 13) median (Q1,Q3)",,,,"10.0 (6.5, 12.0) median (IQR)",,,,,,,,,8,4,13,,,,,,,,,,,,,,,1
40,Yalda,Yang et al.,2020-02-24,https://doi.org/10.1016/S2213-2600(20)30079-5,"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.",2019-12-24,2020-01-26,2020-02-09,China,Wuhan,,52 critically ill adult patients with SARS-CoV-2 pneumonia who were  admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital ,Yes,"single-centered, retrospective, observational study",Death,ICU,critically ill,those admitted to the intensive care unit (ICU) who required mechanical ventilation or had a fraction of inspired oxygen (FiO2) of at least 60% or more.,,,,adult,main,Severe,N,,,,Dead,32,66,Y,64·6 (11·2) mean (SD),,,,64.6,11.2,,,Y,,,7 (I3–11) median (IQR),,,,11 (7–14) median (IQR),,,,,,,,,,,,,,,,,7,3,11,,,"52 patients, LOS only presented for thos that have died but follow up has been completed for all patients",,1
,,Yang et al.,,,,,,,China,,,,Yes,,Survivors,,,,,,,adult,main,Severe,N,,,,Alive,20,70,Y,51·9 (12·9),,,,51.9,12.9,,,Y,,,,,,,9 (6–12),,,,,,,,,,,,,,,,,,,,,,,,1
41,Ellie,Yuan et al.,2020-03-29,10.1007/s00011-020-01342-0,The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients,2020-01-11,2020-02-04,2020-02-13,China,Shenzhen,,94 patients enrolled from Jan 11th 2020 to Feb 4th 2020 in Shenzhen Third People’s Hospital: confirmed covis patients and discharged,Yes,Prospective cohort,Discharged,general,All patients,,,,,adult,main,All,Y,,,,Alive,94,44.7,Y,40 (1–78) median (range),40,,,,,1,78,Y,14.28 (13.61–14.95) mean (95%CI),,,,,,,,,,,,,,,,14.28,3.31,,,,,,,,,,,,,1
,,Yuan et al.,,,,,,,China,,,,Yes,,Discharged,general,Mild,,,,,adult,,Mild,Y,,,,Alive,8,37.5,Y,19 (7–39) median (range),19,,,,,7,39,Y,12.88 (11.36–14.39) mean (95%CI),,,,,,,,,,,,,,,,12.88,2.19,,,,,,,,,,,,,0
,,Yuan et al.,,,,,,,China,,,,Yes,,Discharged,general,Moderate,,,,,adult,,Moderate,Y,,,,Alive,75,45.3,Y,40 (1–78) median (range),40,,,,,1,78,Y,14.12 (13.34–14.90) mean (95%CI),,,,,,,,,,,,,,,,14.12,3.45,,,,,,,,,,,,,0
,,Yuan et al.,,,,,,,China,,,,Yes,,Discharged,general,Severe,,,,,adult,,Severe,Y,,,,Alive,11,45.5,Y,63 (32–69) median (range),63,,,,,32,69,Y,16.36 (14.79–17.93) mean (95%CI),,,,,,,,,,,,,,,,16.36,2.66,,,,,,,,,,,,,0
42,Ellie,Zhang et al.,2020-03-06,https://doi.org/10.1101/2020.03.02.20030452,"Clinical features and outcomesof 221 patients with COVID-19 in Wuhan, China",2020-01-02,2020-02-10,2020-02-15,China,Hubei,Wuhan,"confirmed diagnosed as COVID-19 from January 2 to February 10,  2020 at  Zhongnan  Hospital  of  Wuhan  University,Wuhan,  China",No,Retrospective cohort,Discharge to ward,ICU,,,,,,adult,main,All,N,,,,Alive,23,65.2,Y,62.0(49.0-71.0),62,49,71,,,,,Y,,,8.0(5.0-13.0) median IQR,,,,10.0(7.0-12.0) median IQR,,,,,,,,,,,,,,,,,8,5,13,,,,,1
,,Zhang et al.,,,,,,,China,,,,No,,Death in ICU,ICU,,,,,,adult,main,All,N,,,,Dead,9,77.8,Y,76.0(57.5-81.5),76,57.5,81.5,,,,,Y,,,11.0(4.5-14.5) median IQR,,,,11.0(8.0-12.0) median IQR,,,,,,,,,,,,,,,,,11,4.5,14.5,,,,,1
43,Emily,Zhang et al.,2020-03-26,https://doi.org/10.1101/2020.03.24.20042655,"COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome",,,,China,Shaanxi,,cases of COVID-19 were from Xi’an No.8 Hospital (Shaanxi Provincial Infectious Disease Hospital) and the First Affiliated Hospital of Xi’an Jiaotong University,No,,,,All,,,,,adult,main,All,Y,,,,Alive,28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Doesn't describe patient chars and statistic for non-ICU LOS not specified,,1
,,Zhang et al.,,,,,,,China,,,,No,,,general,Non-ICU,,,,,adult,,Non-severe,Y,,,,Alive,25,,,,,,,,,,,,16.24 ± 2.39,,,,,,,,,,,,,,,,16.24,2.39,,,,,,,,,,,,,0
44,Ellie,Zhao et al. ,2020-03-30,https://doi.org/10.1101/2020.03.13.20035436,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,2020-01-21,2020-02-08,2020-02-29,China,,Beijing,"laboratory-confirmed COVID-19 in Beijing YouAn Hospital, Beijing, China between 21st Jan and 8th Feb 2020",No,Retrospective cohort,Discharge and death,general,All,,,,,adult,main,All,N,,,,All,77,44.2,Y,52±20,,,,52,20,,,Y,13 (10-18) median (IQR),,,,5 (3-6) median (IQR),,,,,,,,,13,10,18,,,,,,,,,,,,,,,1
,,Zhao et al. ,,,,,,,China,,,,No,,Discharge,general,All,,,,,adult,main,All,Y,,,,Alive,64,44.2,N,,,,,52,20,,,N,13 (10-16.5) median (IQR),,,,5 (4-6) median (IQR),18.5 (15-22)/64,,,,,,,,13,10,16.5,,,,,,,,,,,,,,,0
,,Zhao et al. ,,,,,,,China,,,,No,,Discharge,general,Non-severe,,,,,adult,,Non-severe,Y,,,,Alive,54,44.2,N,,,,,52,20,,,N,12 (10-16) median (IQR),,,,5 (4-6) median (IQR),18 (15-21),,,,,,,,12,10,16,,,,,,,,,,,,,,,0
,,Zhao et al. ,,,,,,,China,,,,No,,Discharge,general,Severe,,,,,adult,,Severe,Y,,,,Alive,10,44.2,N,,,,,52,20,,,N,18.5 (15-21) median (IQR),,,,6 (5-7) median (IQR),24.5 (22-27),,,,,,,,18.5,15,21,,,,,,,,,,,,,,,0
,,Zhao et al. ,,,,,,,China,,,,No,,Death,general,,,,,,adult,main,All,N,,,,Dead,5,44.2,N,,,,,52,20,,,N,10 (7-17) median (IQR),,,,4 (2-6) median (IQR),,,16 (9-21) median (IQR),,,,,,10,7,17,,,,,,,,,,,,,,,0
45,Yalda,Zhou et al.,2020-03-11,https://doi.org/10.1016/S0140-6736(20)30566-3,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",,2019-12-29,2020-01-31,China,Hubei,Wuhan,all adult inpatients who were hospitalised for COVID-19 (diagnosed with COVID-19 according to WHO interim guidance) and had a definite outcome (dead or discharged),Yes,retospective cohort,Death or discharge,general/ICU,,,,,,adult,main,All,N,,,,All,191,62,Y,56·0 (46·0–67·0) median (IQR),56,46,67,,,,,Y,11·0 (7·0–14·0) median (IQR),,8·0 (4·0–12·0) median (IQR),,"11·0 (8·0–14·0), median (IQR)",21·0 (17·0–25·0) median (IQR),12·0 (8·0–15·0) median (IQR),,,,,,,11,7,14,,,,,,,,8,4,12,,,"Before Jan 11, 2020, SARS-CoV-2 RNA detection results were not available in the electronic medical records, from which data for this study were obtained retrospectively; therefore, this study includes 29 of the 41 patients originally reported on.","The study dates are based on when patients were discharged or died from hospital - so the first date is based on discharge and not admission. Good study - include lots of inromation, and a resonable sample size",1
,,Zhou et al.,,,,,,,China,,,,Yes,,Death,general/ICU,,,,,,adult,main,All,N,,,,Dead,54,70,Y,69·0 (63·0–76·0),69,63,76,,,,,Y,7·5 (5·0–11·0) median (IQR),,8·0 (4·0–12·0) median (IQR),,"11·0 (8·0–15·0), median (IQR)",18·5 (15·0–22·0),12·0 (8·0–15·0) median (IQR),,,,,,,7.5,5,11,,,,,,,,8,4,12,,,,,0
,,Zhou et al.,,,,,,,China,,,,Yes,,Discharge,general/ICU,,,,,,adult,main,All,N,,,,Alive,137,59,Y,52·0 (45·0–58·0),52,45,58,,,,,Y,12·0 (9·0–15·0) median (IQR),,7·0 (2·0–9·0) median (IQR),,"11·0 (8·0–13·0), median (IQR)",22·0 (18·0–25·0) median (IQR),11·5 (8·0–14·0) median (IQR),,,,,,,12,9,15,,,,,,,,7,2,9,,,,,0
46,Ellie,Wang et al.,2020-04-10,https://doi.org/10.1101/2020.04.07.20057299,"Survival analysis of hospital length of stay of novel coronavirus (COVID-19) pneumonia patients in Sichuan, China",2020-01-16,2020-03-04,2020-03-04,China,Sichuan,,"laboratory-confirmed  cases  of  COVID-19,  which  were  reported  to  the  Sichuan  Center  for  Disease  Control  and  Prevention  (CDC)  through  the  National  Notifiable  Diseases  Reporting  System  (NNDRS).",No,Cross-sectional,Dead or discharged,general,All,,,,,adult,main,All,Y,,,,All,538,53,Y,,,,,,,,,,19 (14-23) median IQR,,,,,,,,,,,,,19,14,23,,,,,,,,,,,,,,"Not clear whether patients still-hospitalised were included in the LOS estimate, we have assumed that still-hospitalised patients were included.",1
,,Wang et al.,,,,,,,,,,,No,,,general,Mild,,,,,adult,,Mild,Y,,,,All,450,53,N,,,,,,,,,,19 (14-23) median IQR,,,,,,,,,,,,,19,14,23,,,,,,,,,,,,,,,0
,,Wang et al.,,,,,,,,,,,No,,,general,Severe,,,,,adult,,Severe,Y,,,,All,88,53,N,,,,,,,,,,23 (15-26) median IQR,,,,,,,,,,,,,23,15,26,,,,,,,,,,,,,,,0
47,Ellie,Wu et al.,2020-04-09,https://doi.org/10.1101/2020.03.30.20047365,Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications,,2020-02-26,2020-02-26,China,Shanghai,,adult COVID-19 patients admitted to Shanghai Public  Health  Clinical  Center.  ,Yes,Cohort,Discharge,general,All,,,,,adult,main,All,N,,,,All,175,47,Y,50  (range 16 to 85 ),50,,,,,16,85,Y,16  (7 -30) meadian range,,,,,,,,,,,,,16,7,30,,,,,,,,,,,,,,Only enrolled discharged and mild patients. No start date for the study provided.,1
,,,,,,,,,,,,,Yes,,,general,Low,titers of SARS-CoV-2-specific NAbs ,,,,adult,,All,N,Titres NAbs - low,,Titres NAbs - low,All,52,36.5,Y,38 (16-68),38,,,,,16,68,Y,14.5 (8-29),,,,,,,,,,,,,14.5,8,29,,,,,,,,,,,,,,,0
,,,,,,,,,,,,,Yes,,,general,medium-low,,,,,adult,,All,N,Titres NAbs - medium-low,,Titres NAbs - medium-low,All,29,44.8,Y,42 (23-75),42,,,,,23,75,Y,15 (7-28),,,,,,,,,,,,,15,7,28,,,,,,,,,,,,,,,0
,,,,,,,,,,,,,Yes,,,general,medium high,,,,,adult,,All,N,Titres NAbs - medium-high,,Titres NAbs - medium-high,All,69,52.2,Y,56 (23-77),56,,,,,23,77,Y,16 (8-30),,,,,,,,,,,,,16,8,30,,,,,,,,,,,,,,,0
,,,,,,,,,,,,,Yes,,,general,high,,,,,adult,,All,N,Titres NAbs - high,,Titres NAbs - high,All,25,56,Y,63 (35-85),63,,,,,35,85,Y,18 (10-29),,,,,,,,,,,,,18,10,29,,,,,,,,,,,,,,,0
48,Ellie,Yin et al.,2020-04-11,https://doi.org/10.1101/2020.04.07.20053744,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Pregnancy In China: A Retrospective Cohort Study,2020-01-28,2020-02-28,2020-03-08,China,Hubei,Wuhan,"female inpatients (20-40 years old, female) from Jan 28 to Feb 28, 2020, at Wuhan Union and Tongji hospitals of Huazhong University of Science and Technology",No,Cohort,Discharge,general,All,,,,,adult,main,All,N,,,,Alive,66,0,Y,20-40,30,,,,,20,40,Y,17·8±6·1 mean SD,,,,10·7±8·1,,,,,,,,,,,,17.8,6.1,,,,,,,,,,,,"Only include pregnant women. Not clear whether patients still-hospitalised were included in the LOS estimate, we have assumed that still-hospitalised patients were included.",1
,,,,,,,,,,,,,No,,,general,Pregnant,,,,,adult,,All,N,Pregnant,,Pregnant,Alive,31,0,Y,31·0±4.3,,,,31,4.3,,,Y,17·3±6·9,,,,7·8±7·0,,,,,,,,,,,,17.3,6.9,,,,,,,,,,,,,0
,,,,,,,,,,,,,No,,,general,Non-pregnant,,,,,adult,,All,N,Non-pregnant,,Non-pregnant,Alive,35,0,Y,32·9±4·8,,,,32.9,4.8,,,Y,18·2±5·6,,,,13·2±8·2,,,,,,,,,,,,18.2,5.6,,,,,,,,,,,,,0
49,Ellie,Tian et al.,2020-04-07,https://doi.org/10.1101/2020.04.04.20053280,Longitudinal analysis of laboratory findings during the process of recovery for patients with COVID-19,2020-01-21,2020-03-05,,China,Jilin,,"three designated tertiary hospitals in Jilin province including the First Hospital of Jilin University (n=3), Changchun Infectious Disease Hospital (n=42), and Siping Infectious Disease Hospital (n=14)",Yes,Cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,59,57.6,Y,41 years (IQR: 29-52),41,29,52,,,,,Y,17 (11-20) median IQR,,,,,,,,,,,,,17,11,20,,,,,,,,,,,,,,Dates are different in abstract and main text,1
50,Ellie,Petrilli et al.,2020-04-11,https://doi.org/10.1101/2020.04.08.20057794,"Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New York City",2020-03-01,2020-04-02,2020-04-07,USA,New York,New York,all patients with laboratory-confirmed Covid-19 treated at an academic health system in New York City (NYU Langone Health),No,Cross-sectional,Discharge or death,general,All,,,,,adult,main,All,Y,,,,All,1273,50.5,Y,"52 years (interquartile range, 36 to 65)",52,36,65,,,,,Y,"4.8 days (interquartile range, 3.3 to 7.6",,,,,,,,,,,,,4.8,3.3,7.6,,,,,,,,,,,,,,"In the critical illness, some patients still hospitalised at the end of the study (using figure 1 I removed these from the study sample size for critical patients). In the non-critical all patients discharged (no deaths)",1
,,,,,,,,,,,,,No,,Discharge,general,Non-critical,,,,,adult,,Non-severe,Y,,,,Alive,932,60.1,Y,58 (46-71),58,46,71,,,,,Y,4 (2-6) median IQR,,,,,,,,,,,,,4,2,6,,,,,,,,,,,,,,,0
,,,,,,,,,,,,,No,,Discharge or death,general,Critical,,,,,adult,,Severe,Y,,,,All,341,68,Y,67 (56-77),67,56,77,,,,,Y,6 (3-9),,,,,,,,,,,,,6,3,9,,,,,,,,,,,,,,,0
51,Yalda,Zeng et al.,2020-04-11,https://doi.org/10.1101/2020.04.06.20054825,"Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",2020-01-05,2020-03-08,2020-03-08,China,Hubei,Wuhan,"Hankou Hospital, patients >= 18 years, entire stay in hospital >=48 hours. Confirmed cases of COVID-19",No,Cohort,Discharge or death,general,All,,,,,adult,main,All,N,,,,All,274,55,Y,60 (15) mean (SD),,,,60,15,,,Y,20 (14-27) median (IQR),,,,,,,,,,,,,20,14,27,,,,,,,,,,,,,,"Excluding short hospital stays (<less 48 hours). Not clear whether LOS estimate includes still-hospitalised patients, or only those who are discharges/dead. ",1
,,,,,,,,,,,,,No,,Discharge or death,general,Hypertension,,,,,adult,,All,N,Hypertension,,Hypertension,All,75,55,Y,67 (11) mean (SD),,,,67,11,,,Y,22 (15-26) median (IQR),,,,,,,,,,,,,22,15,26,,,,,,,,,,,,,,% male in hypertension group is different in tables 1 and 2 - not sure why?,0
,,,,,,,,,,,,,No,,Discharge or death,general,Hypertension - ACEI/ARB previous treatment,,,,,adult,,All,N,Hypertension - ACEI/ARB previous treatment,,Hypertension - ACEI/ARB previous treatment,All,28,43,Y,64 (12) mean (SD),,,,64,12,,,Y,21 (15-25) median (IQR),,,,,,,,,,,,,21,15,25,,,,,,,,,,,,,,,0
,,,,,,,,,,,,,No,,Discharge or death,general,Hypertension - no ACEI/ARB previous treatment,,,,,adult,,All,N,Hypertension - no ACEI/ARB previous treatment,,Hypertension - no ACEI/ARB previous treatment,All,47,49,Y,69 (10) mean (SD),,,,69,10,,,Y,22 (16-28) median (IQR),,,,,,,,,,,,,22,16,28,,,,,,,,,,,,,,,0
,,,,,,,,,,,,,No,,Discharge or death,general,Non-Hypertension,,,,,adult,,All,N,Non-Hypertension,,Non-Hypertension,All,199,55,Y,58 (15) mean (SD),,,,58,15,,,Y,19 (13-28) median (IQR),,,,,,,,,,,,,19,13,28,,,,,,,,,,,,,,,0
52,Yalda,Xiao et al.,2020-04-08,https://doi.org/10.1101/2020.04.06.20055194,"Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",2020-01-05,2020-03-08,2020-03-08,China,Hubei,Wuhan,"Hankou Hospital, COVID-19 confirmed patients >=18 years, entire stay in hospital >=48 hours, not
undergone renal replacement therapy (RRT) before admission",No,Cohort,Discharge or death,general,All,,,,,adult,main,All,N,,,,All,287,55.7,Y,62 (51-70) median (IQR),62,51,70,,,,,Y,18 (12 -23) median (IQR),,,,,,,,,,,,,18,12,23,,,,,,,,,,,,,,"Not clear whether LOS estimate includes still-hospitalised patients, or only those who are discharges/dead. ",1
,,,,,,,,,,,,,No,,Discharge or death,general,Non-Acute Kidney Injury (AKI),,,,,adult,,All,N,Non-Acute Kidney Injury (AKI),,Non-Acute Kidney Injury (AKI),All,232,52.6,Y,60 (49-69) median (IQR),60,49,69,,,,,Y,18 (13 -23) median (IQR),,,,,,,,,,,,,18,13,23,,,,,,,,,,,,,,,0
,,,,,,,,,,,,,No,,Discharge or death,general,AKI - stage 1,"Stage 1: Increase in serum creatinine to 1.5 to 1.9 times baseline, or increase
 in serum creatinine by ≥26.5 μmol/L.",,,,adult,,All,N,AKI - stage 1,,AKI - stage 1,All,41,69.1,N,67 (57-74) median (IQR),67,57,74,,,,,N,22.5 (8.3 - 28) median (IQR),,,,,,,,,,,,,22.5,8.3,28,,,,,,,,,,,,,,,0
,,,,,,,,,,,,,No,,Discharge or death,general,AKI - stage 2&3,"Stage 2: Increase in serum creatinine to 2.0 to 2.9 times baseline.
 Stage 3: Increase in serum creatinine to 3.0 times baseline, or increase in serum creatinine to ≥353.6
 μmol/L, or the initiation of renal replacement therapy.",,,,adult,,All,N,AKI - stage 2&3,,AKI - stage 2&3,All,14,69.1,N,68 (57-74) median (IQR),68,57,74,,,,,N,12 (4.5 - 17.8),,,,,,,,,,,,,12,4.5,17.8,,,,,,,,,,,,,,,0
53,Ellie,Cheng et al.,2020-03-20,https://doi.org/10.1016/j.kint.2020.03.005,Kidney disease is associated with in-hospital death of patients with COVID-19,2020-01-28,2020-02-11,,China,Hubei,Wuhan,"All consecutive patients with COVID-19 admitted to Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",No,Cohort,Death,general,,,,,,adult,main,All,N,,,,Dead,113,52.4,N,63 (50–71),63,50,71,,,,,N,"6 days (interquartile range, 3–12 days)",,,,,,,,,,,,,6,3,12,,,,,,,,,,,,,,"Assumes that median time to death is time from admission to death. But the numbers add up from table 1. Age and sex for the overall population, not just deaths",1